Dayvigo (Lemborexant) in Special Populations: Transplant, HIV, Hepatic Impairment, and Beyond

Dayvigo (lemborexant) is an FDA-approved dual orexin receptor antagonist (DORA) for treating insomnia in adults, administered as a 5 mg or 10 mg dose at bedtime. While suvorexant (Belsomra) and daridorexant (Quviviq) belong to the same DORA class, they are distinct medications with different half-lives and drug interaction patterns from lemborexant. In generally healthy patients, lemborexant dosing presents no special complexity. In patients taking immunosuppressants, boosted antiretrovirals, or those with hepatic impairment, the clinical decision rarely hinges on the severity of insomnia alone. Rather, it depends on whether concurrent medications and hepatic function may elevate lemborexant concentrations to potentially toxic levels.

The core clinical fact governing this entire page: lemborexant is cleared almost exclusively through CYP3A4, so its safety in transplant recipients, people with HIV, and patients with liver disease depends on the CYP3A4 activity of their other medications and their hepatic function, not on age or renal function alone. FDA labeling contraindicates lemborexant with strong CYP3A4 inhibitors and caps the dose at 5 mg with moderate inhibitors or moderate hepatic impairment, while renal impairment requires no dose change because less than 1% of the dose is excreted unchanged in urine. That single pharmacokinetic map, not a population label like "elderly" or "transplant," is what should drive the prescribing decision.

What is established, what is plausible, and what is not established

Established, from FDA labeling: lemborexant is metabolized primarily by CYP3A4; strong CYP3A4 inhibitors are contraindicated; the dose is capped at 5 mg with moderate CYP3A4 inhibitors or moderate hepatic impairment (Child-Pugh B); lemborexant is not recommended in severe hepatic impairment (Child-Pugh C); no dose adjustment is required for renal impairment; lemborexant has not been studied in patients on dialysis; there is insufficient human pregnancy and lactation data.

Plausible but not directly studied: the magnitude and clinical significance of specific immunosuppressant or antiretroviral interactions (tacrolimus, cyclosporine, boosted protease inhibitors) with lemborexant specifically, as opposed to interactions inferred from CYP3A4 class pharmacology. We did not find a dedicated pharmacokinetic study of lemborexant combined with tacrolimus or cyclosporine, and readers should not treat class-based inference as equivalent to a trial in that population.

Not established: safety and dosing in decompensated cirrhosis, dialysis, or pregnancy; any claim about lemborexant reducing fall or fracture risk in older adults compared with other hypnotics in real-world use, which has not been directly tested outside of controlled trial postural-stability measures.

How lemborexant works, and why that matters for interaction risk

Lemborexant blocks orexin-1 (OX1R) and orexin-2 (OX2R) receptors in the hypothalamus, reducing the wake-promoting orexin signal rather than broadly sedating GABAergic or histaminergic circuits the way benzodiazepines, Z-drugs, and sedating antihistamines do. This mechanistic difference is why DORAs are generally considered to carry a lower respiratory-depression burden than older hypnotics, though head-to-head data across patient populations are limited and this should not be read as a guarantee of safety in patients with significant respiratory disease.

The FDA's pivotal trials for lemborexant (the SUNRISE program) enrolled adults aged 55 and older and reported improvement in sleep onset and maintenance versus placebo, with next-morning postural stability testing not showing a meaningful difference from placebo at the doses studied. Readers who need the exact trial numbers for a clinical decision should verify them against the original publication rather than relying on a secondhand summary, since we could not independently confirm the specific figures cited in earlier drafts of this material.

The CYP3A4 gateway: the fact that governs every other section

Because CYP3A4 does nearly all the metabolic work, three categories of co-medication change lemborexant's risk-benefit calculus:

• Strong CYP3A4 inhibitors (examples include ketoconazole, itraconazole, voriconazole, clarithromycin, ritonavir, and cobicistat) are contraindicated with lemborexant per FDA labeling. The label describes a substantial increase in lemborexant exposure with strong inhibitors; readers who need the precise fold-change for a specific clinical scenario should confirm the current figure directly from the FDA label rather than treat any single number as fixed, since labeling can be updated.
• Moderate CYP3A4 inhibitors cap the recommended dose at 5 mg.
• Strong CYP3A4 inducers (rifampin, carbamazepine, St. John's wort) can reduce lemborexant levels enough to cause therapeutic failure.

Any clinician considering lemborexant for a medically complex patient should map the full CYP3A4 interaction profile of the current regimen before prescribing, using the current FDA label as the primary reference (Dayvigo prescribing information).

Organ transplant recipients

Insomnia is common after solid organ transplantation, driven by corticosteroids, pain, and anxiety, though the exact prevalence range varies by study population and we recommend confirming any specific percentage against a current transplant-medicine source rather than repeating a single figure as universal. The bigger issue for prescribing is that the most common maintenance immunosuppressants interact with CYP3A4.

Tacrolimus is a CYP3A4 substrate and a weak inhibitor. There is no published dedicated pharmacokinetic study of lemborexant combined with tacrolimus. Based on class pharmacology, tacrolimus interaction falls under the FDA's moderate-inhibitor guidance, meaning a 5 mg lemborexant ceiling and closer attention to tacrolimus trough levels is a reasonable, cautious approach, though the specific monitoring interval is site judgment rather than a labeled requirement.

Cyclosporine is both a CYP3A4 substrate and a moderate-to-strong inhibitor depending on dose and timing post-transplant. At the higher doses used early after transplant, avoiding lemborexant or limiting to 5 mg with close monitoring is the more conservative approach given the compounded exposure risk.

Sirolimus and everolimus are CYP3A4 substrates without meaningful inhibitory activity, which makes the bidirectional interaction concern smaller than with tacrolimus or cyclosporine. This does not mean the combination has been studied directly; it means the theoretical risk is lower.

People living with HIV

Sleep disturbance is reported at high rates among people living with HIV, though exact prevalence estimates vary across studies and populations; a single number should not be treated as fixed. The more actionable issue is that many antiretroviral regimens use CYP3A4-active boosting agents.

Ritonavir and cobicistat, used as pharmacokinetic boosters with protease inhibitors and some integrase inhibitors, are strong CYP3A4 inhibitors. Lemborexant is contraindicated in patients on these boosted regimens per FDA labeling.

Efavirenz is a moderate CYP3A4 inducer and independently causes CNS effects such as vivid dreams and insomnia that overlap with the symptom lemborexant is meant to treat. Combining the two is not contraindicated but may be pharmacologically counterproductive: the inducer effect can blunt lemborexant's benefit while efavirenz continues to drive the underlying sleep complaint.

Unboosted regimens such as dolutegravir, bictegravir without cobicistat, raltegravir, and doravirine do not meaningfully affect CYP3A4. These represent the more straightforward backbone for concomitant lemborexant use, though "more straightforward" describes the absence of a known metabolic conflict, not direct trial evidence of safety in this specific combination.

Hepatic impairment

Liver function is the single largest determinant of lemborexant clearance. FDA-labeled Child-Pugh stratification:

• Mild impairment (Child-Pugh A): no dose adjustment required.
• Moderate impairment (Child-Pugh B): maximum recommended dose is 5 mg nightly.
• Severe impairment (Child-Pugh C): lemborexant has not been studied and is not recommended.

Patients with compensated cirrhosis or NASH generally fall into the moderate-impairment caution range and should default to the 5 mg cap. Patients with decompensated cirrhosis, ascites, or hepatic encephalopathy should not receive lemborexant. Adding any CYP3A4 inhibitor on top of hepatic impairment compounds exposure in a way that is not predictable from either factor alone, which is a reason to choose a different agent rather than stack a moderate inhibitor onto an already-capped dose.

Renal impairment

Lemborexant undergoes negligible renal elimination, and FDA labeling states no dose adjustment is needed across mild, moderate, or severe renal impairment. It has not been studied in patients on dialysis, so prescribing in that group is a matter of clinical judgment rather than labeled guidance. Because clearance is hepatic rather than renal, lemborexant avoids the active-metabolite accumulation problem that makes some benzodiazepines and Z-drugs riskier in chronic kidney disease, though this is a pharmacologic rationale rather than a direct comparative trial finding.

Older adults

The pivotal SUNRISE trials enrolled adults 55 and older and reported no clinically meaningful difference from placebo on next-morning postural stability testing at the doses studied. The American Geriatrics Society's Beers Criteria have historically flagged benzodiazepines and Z-drugs as potentially inappropriate in adults 65 and older due to fall and cognitive risk; DORAs including lemborexant are not on that list, though readers should confirm the current Beers Criteria edition directly, since these lists are periodically revised.

There is no mandatory dose reduction for age alone in FDA labeling; the standard 5 mg starting dose applies across adults. In practice, older adults are more likely to have hepatic impairment or polypharmacy that independently caps the dose at 5 mg, so age often correlates with a lower effective dose without age itself being the labeled reason.

Oncology patients

Cancer treatment commonly involves CYP3A4-active drugs on both sides of the interaction. Azole antifungals used for fungal prophylaxis in neutropenic patients (itraconazole, voriconazole) are strong inhibitors and contraindicate lemborexant. Aprepitant, used for chemotherapy-induced nausea, is a moderate inhibitor and would cap lemborexant at 5 mg. Dexamethasone at oncologic doses is a weak-to-moderate CYP3A4 inducer and is itself a common cause of steroid-related insomnia, creating a scenario where the drug driving the insomnia may also reduce lemborexant's effectiveness. Reassessing the dose after a steroid course ends is a reasonable precaution against oversedation once the inducer effect resolves.

Pregnancy and lactation

Animal studies at doses well above the human therapeutic range showed decreased fetal weight and increased skeletal variations; adequate human data do not exist. FDA labeling states there is insufficient information in pregnant patients, and lemborexant has been detected in rat milk with no available human lactation data. For pregnant or breastfeeding patients with insomnia, cognitive behavioral therapy for insomnia (CBT-I) is the first-line approach recommended in current obstetric guidance (ACOG clinical guidance).

A CYP3A4-first decision framework for special populations

Use this sequence before writing a lemborexant prescription for any medically complex patient. It is a practical organizing tool built from the FDA labeling facts above, not a substitute for a full medication reconciliation or a substitute for individualized dosing advice from the treating clinician.

Step 1: List every CYP3A4-active drug the patient currently takes. Strong inhibitors (ketoconazole, itraconazole, voriconazole, clarithromycin, ritonavir, cobicistat) → stop here. Lemborexant is contraindicated regardless of any other factor.

Step 2: If no strong inhibitor is present, check for a moderate inhibitor. Examples relevant to the populations above include cyclosporine at higher doses, tacrolimus, aprepitant, and fluconazole above 200 mg daily. Any one of these caps the dose at 5 mg.

Step 3: Check hepatic function independently of the medication list. Moderate hepatic impairment (Child-Pugh B) caps the dose at 5 mg on its own. Severe impairment (Child-Pugh C) means lemborexant is not recommended, full stop, regardless of the medication list.

Step 4: If both a moderate inhibitor and moderate hepatic impairment are present at the same time, do not simply apply the 5 mg cap from either factor alone. The combination is not well characterized and the compounding exposure risk is a reason to choose a different insomnia treatment rather than stack two caution flags onto one dose.

Step 5: Confirm renal function does not change the plan. Renal impairment, including severe impairment, does not require a dose change based on current labeling. Dialysis patients fall outside labeled experience and warrant individualized judgment rather than a default dose.

Step 6: Reassess after any change to the CYP3A4 environment. Starting or stopping an azole antifungal, a boosted antiretroviral, or a short steroid pulse should trigger a fresh look at the lemborexant dose, since the interaction status can change mid-course of treatment.

When to escalate to urgent evaluation: excessive daytime sedation, confusion, difficulty waking, or signs of complex sleep-related behavior (activities performed with no memory of them) after starting or adjusting lemborexant warrant contacting the prescriber promptly rather than waiting for a routine follow-up, particularly in patients who have just added or removed a CYP3A4-active drug.

Practical summary

Start with the CYP3A4 interaction map, not the diagnosis label of "transplant patient" or "elderly patient." A strong inhibitor rules lemborexant out entirely. A moderate inhibitor or moderate hepatic impairment caps the dose at 5 mg. Both together argue for a different agent. Renal impairment, on its own, changes nothing. Age, on its own, changes nothing in the label, though it often correlates with the other factors that do.

References

1. U.S. Food and Drug Administration. Dayvigo (lemborexant) prescribing information, 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212028s000lbl.pdf
2. American College of Obstetricians and Gynecologists. Clinical guidance for the integration of the findings of the USPSTF, 2023. https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2023/06/clinical-guidance-for-the-integration-of-the-findings-of-the-uspstf

This article references the SUNRISE-1 and SUNRISE-2 lemborexant trials, an American Academy of Sleep Medicine insomnia pharmacotherapy guideline, and HIV and transplant sleep-epidemiology literature by name. A primary-source search for this topic did not return verifiable identifiers for those specific papers, so their citation links have been removed rather than pointing to unverified or possibly mismatched sources. Anyone relying on exact trial figures, prevalence percentages, or guideline wording from those studies should locate and confirm the original publication before using the number in a clinical or patient-facing context.